Publications and Presentations

Date Title Meeting/Publication Link
July 9-12, 2021 Impact of one or more comorbidities and the microbiome metabolic therapy (MMT) KB109 on symptom resolution in non-hospitalized patients with mild to moderate COVID-19 ECCMID 2021 | European Congress of Clinical Microbiology and Infectious Diseases Click here
June 20-24, 2021 Targeting the Microbiome with KB109 in Mild to Moderate COVID-19 Reduced Healthcare Utilization and Symptom Duration World Microbe Forum 2021 Click here
May 10–15, 2021 Patient-Reported Comorbidity Affects Symptom Duration in Non-Hospitalized Patients with Mid-to-Moderate COVID-19 in a Clinical Study Immunology 2021 | AAI Click here
November 13-16, 2020 KB39, a novel synthetic glycan modulating the gut microbiome, decreases fatty liver and atherosclerosis in diet-induced murine models of non-alcoholic fatty liver and cardiovascular disease The Liver Meeting Digital Experience | AASLD Click here
November 13-16, 2020 Community shift in the gut microbiome is a potential mechanism for reduction in gut microbiota-associated ammonia by the novel synthetic glycan, KB174, in patients with well-compensated cirrhosis The Liver Meeting Digital Experience | AASLD Click here
Oct. 21-25, 2020 Development of a Novel Synthetic Glycan to Prevent Bacterial Infections and Ameliorate Respiratory Viral Infections IDWeek 2020™ Click here
August 27-29, 2020 KB174 Reduces Relative Abundance of Multidrug Resistant (MDR) Enterobacteriaceae in Fecal Samples From Patients With Cirrhosis in an Ex Vivo Assay The Digital International Liver Congress™ 2020 Click here
August 27-29, 2020 A Randomized, Double-Blind Study to Evaluate the Safety and Tolerability of KB174, a Novel Synthetic Glycan, in Patients With Well-Compensated Cirrhosis The Digital International Liver Congress™ 2020 Click here
August 27-29, 2020 Microbiome Metabolic Therapies Reduce Microbiota-Associated Ammonia in Ex Vivo Fecal Samples From Healthy Subjects and Patients With Minimal Hepatic Encephalopathy and Demonstrate Improved Tolerability Over Lactulose in a Clinical Study The Digital International Liver Congress™ 2020 Click here
October 6-10, 2019 Chemical Modulation of the Gut Microbiome Alleviates Chemotherapy-Induced Toxicity Keystone Symposia on Molecular and Cellular Biology I Microbiome: Therapeutic Implications Click here
October 2-6, 2019 Novel Glycans Reduce Carbapenem-resistant Enterobacteriaceae (CRE) and Vancomycin-resistant Enterococcus (VRE) Colonization in an Ex Vivo Assay by Supporting Growth of Commensal Microbiota at the Expense of Multidrug-Resistant (MDR) Organisms IDWeek 2019™ Click here
September 3-6, 2019 An Open-Label, Single-Arm Clinical Study to Evaluate Safety and Tolerability of KB195, A Novel Glycan, in Patients with Urea Cycle Disorders SSIEM/ Society for the Study of Inborn Errors of Metabolism Annual Symposium Click here
April 12, 2019 Identification of Novel Glycans That Target Gut Microbiota-Associated Ammonia Production EASL | The International Liver Congress™ 2019 Click here
April 7, 2019 KB195, a Novel Glycan, Modulates Ammonia Metabolism in Healthy Subjects and in Microbiome Samples Collected From Patients With Urea Cycle Disorders Society for Inherited Metabolic Disorders (SIMD), 41st Annual Meeting Click here
March 12, 2019 Developing a Drug Discovery Platform to Target Gut Microbiota-Associated Ammonia Production Keystone Symposia, Microbiome: Chemical Mechanisms and Biological Consequences Click here
September 18, 2018 Microbiome Metabolic Therapies (MMTs) reduce pathogen colonization in ex vivo testing of intensive care unit patient microbiomes EMBO | EMBL Symposium: The Human Microbiome Click here

Additional References

Viewing these publications requires you to leave Kaleido Biosciences’ website. Kaleido assumes no responsibility for the
information, statements or other content you may encounter on third-party websites.

Date Title Meeting/Publication Link
February 11, 2020 Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth Cell Reports Click here
July 22, 2019 Microbiota-derived acetate protects against respiratory syncytial virus infection through a GPR43-type 1 interferon response Nature Communications Click here
December 10, 2018 Gut microbiome structure and metabolic activity in inflammatory bowel disease Nature Microbiology Click here
November 5, 2018 Inulin-type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels Gut Microbes Click here
June 28, 2018 Impact of gut colonization with butyrate producing microbiota on respiratory viral infection following allo-HCT Blood Click here
May 15, 2018 Dietary Fiber Confers Protection against Flu by Shaping Ly6c- Patrolling Monocyte Hematopoiesis and CD8+T Cell Metabolism Immunity Click here
January 5, 2018 Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors Science Click here
November 25, 2014 A perspective on the complexity of dietary fiber structures and their potential effect on the gut microbiota Journal of Molecular Biology Click here
April 24, 2013 Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk New England Journal of Medicine Click here
April 11, 2012 How glycan metabolism shapes the human gut microbiota Nature Reviews Microbiology Click here
March 29, 2011 Microbiota regulates immune defense against respiratory tract influenza A virus infection Proceedings of the National Academy of Sciences Click here
March 11, 2006 Effect of lactulose and Saccharomyces boulardii administration on the colonic urea‐nitrogen metabolism and the bifidobacteria concentration in healthy human subjects Alimentary Pharmacology & Therapeutics Click here